At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Sep 14, 2026 at 04:00 ET
BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart in squamous NSCLC patients who progressed on prior immunotherapy and chemotherapy. Gotistobart nearly doubled median OS to 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295), a statistically significant and clinically meaningful result. The data were presented at WCLC 2026 and support the ongoing pivotal stage 2 of the trial.
- Gotistobart showed median OS of 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295)
- Data from non-pivotal stage 1 of PRESERVE-003 Phase 3 trial in squamous NSCLC patients after prior immunotherapy and chemotherapy
- Pivotal stage 2 of PRESERVE-003 is ongoing at >160 sites globally
- Gotistobart received Fast Track Designation from FDA (2022) and Orphan Drug Designation for squamous NSCLC (2025)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access